Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.50 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.49 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752259 | 0.82 | PLA2G2C (0.46) | — | |
| Dexfosfoserine SCHEMBL2877716 | 0.82 | P2RY10 (0.46) | P2RY10GPR34GPR174 | |
| SCHEMBL26642945 | 0.80 | P2RY10 (0.58) | P2RY10GPR34GPR174 | |
| SCHEMBL1534116 | 0.80 | P2RY10 (0.58) | P2RY10GPR34GPR174 | |
| SCHEMBL1963907 | 0.79 | PLA2G2C (0.44) | P2RY10GPR34 | |
| SCHEMBL1965773 | 0.79 | PLA2G2C (0.44) | P2RY10GPR34 | |
| SCHEMBL4444982 | 0.79 | PLA2G2C (0.44) | P2RY10GPR34 | |
| SCHEMBL2311014 | 0.79 | PLA2G2C (0.44) | P2RY10GPR34 | |
| SCHEMBL4435691 | 0.79 | PLA2G2C (0.44) | P2RY10GPR34 | |
| SCHEMBL8694073 | 0.79 | P2RY10 (0.60) | P2RY10GPR34GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301341-A1 | LOADING OF ALGINATE MICROSPHERES | Board of Regents, The University of Texas System (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-4259099-A1 | BIOLOGICAL DELIVERY SYSTEMS | Particella, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022260678-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022132678-A1 | BIOLOGICAL DELIVERY SYSTEMS | DNALITE THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-3982932-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | Dnalite Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3972566-A1 | RADIOTHERAPEUTIC MICROSPHERES | Board of Regents, The University of Texas System (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2021119585-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2020252375-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020237042-A1 | RADIOTHERAPEUTIC MICROSPHERES | PHILLIPS WILLIAM T (US) | 2020-11-26 | — | — | WO | disclosed |
| EP-3538075-A1 | STRUCTURES AND METHODS FOR GENE THERAPY | Dnalite Therapeutics, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089799-A1 | STRUCTURES AND METHODS FOR GENE THERAPY | DNALITE THERAPEUTICS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2016036735-A1 | LIPOSOME-BASED MUCUS-PENETRATING PARTICLES FOR MUCOSAL DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-03-10 | — | — | WO | disclosed |
| EP-2430151-A2 | MENIGOCOCCUS VACCINE CONTAINING LIPOOLIGOSACCHARIDE (LOS) FROM MODIFIED STRAINS OF L6 IMMUNOTYPE NEISSERIA MENINGITIDIS | Sanofi Pasteur (FR) | 2012-03-21 | — | — | EP | disclosed |
| EP-2429658-A2 | METHOD FOR ADMIXING THE LIPOPOLYSACCHARIDE (LPS) OF GRAM-NEGATIVE BACTERIA | Sanofi Pasteur (FR) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130898-A2 | MENIGOCOCCUS VACCINE CONTAINING LIPOOLIGOSACCHARIDE (LOS) FROM MODIFIED STRAINS OF L6 IMMUNOTYPE NEISSERIA MENINGITIDIS | SANOFI PASTEUR (FR) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130896-A2 | METHOD FOR ADMIXING THE LIPOPOLYSACCHARIDE (LPS) OF GRAM-NEGATIVE BACTERIA | SANOFI PASTEUR (FR) | 2010-11-18 | — | — | WO | disclosed |
| WO-2004080396-A2 | LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER | THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (US) | 2004-09-23 | — | — | WO | disclosed |